CORRECT: Abingdon Health receives grant to develop malaria tests

(Correcting erroneous currency) (Alliance News) - Abingdon Health PLC on Monday said it had been ...

Alliance News 28 January, 2025 | 11:35AM
Email Form Facebook Twitter LinkedIn RSS

(Correcting erroneous currency)

(Alliance News) - Abingdon Health PLC on Monday said it had been allocated GBP800,000 worth of funds to develop malaria tests.

The London-based developer of rapid-flow diagnostic tests is among several institutes to receive grant money from UK Research & Innovation, a government authority funded by the Department for Science, Innovation & Technology.

A total of EUR5 million has been set aside for malaria intervention as part of the government's Horizon Europe Guarantee scheme. The project is expected to start in February and continue over the course of two years.

Abingdon's shares were up 3.0% at 8.50 pence each on Tuesday morning in London.

The company is tasked with developing rapid point-of-care tests to detect plasmodium vivax, a malaria-causing bacterium. The test should replicate laboratory-based methods, but must "translate from small-to-medium enterprise prototype to African-based industrial design".

The goal is to meet the World Health Organisation's preferred traits for in-field testing. Once complete, Abingdon will transfer the test to diaTROPIX, a Senegalese manufacturer based at Institut Pasteur Dakar, who will produce more tests locally.

The London-based firm promised to support diaTROPIX in delivering tests "to African communities, particularly those in sub-Saharan Africa".

Chief Executive of Abingdon Chris Yates commented: "We are delighted to have won this grant award as part of a world-leading group of institutions. We are excited to add Abingdon Health's rapid diagnostic test development and manufacturing scale-up expertise to that of our distinguished group of partners."

Other bodies to receive funding include Institut Pasteur, Armauer Hansen Research Institute and the London School of Hygiene & Tropical Medicine.

By Holly Munks, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2025 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Abingdon Health PLC 8.00 GBX 0.00 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures